Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients

Uemura, Naomi; Kodama, Satoru; Nomi, Nozomi; Okamoto, Tomoyo; Suzuki, Masashi

doi:10.3109/00016480903555416

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,38 Overexpression of survivin/BIRC5 has been observed in various cancer types, including HNSCC, and has been linked to increased cell proliferation, invasion, metastasis, and enhanced cell survival, protecting tumor cells from apoptosis. 20,[39][40][41][42] Similar to previous studies, 13,43 we show that BIRC5 expression is higher in tumoral tissue than in adjacent tissue. Interestingly, we also demonstrate, for the first time to our knowledge, that BIRC5 expression is higher in peri-tumoral tissue than in healthy tissue, and we found a positive association between the three tissue types from the same patient.…”

Section: Radiation-induced Survivin/birc5 Expression Is Dependent On ...supporting

confidence: 89%

Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma

Benaiges,

Ceperuelo‐Mallafré,

Guaita

et al. 2024

Head & Neck

View full text Add to dashboard Cite

BackgroundMetabolic reprogramming and abnormal glucose metabolism are hallmarks of head and neck squamous cell carcinoma (HNSCC). Certain oncogenes can promote cancer‐related metabolic changes, but understanding their crosstalk in HNSCC biology and treatment is essential for identifying predictive biomarkers and developing target therapies.MethodsWe assessed the value of survivin/BIRC5 as a radioresistance factor potentially modulated by glucose for predicting therapeutic sensitivity and prognosis of HNSCC in a cohort of 32 patients. Additionally, we conducted in vitro experiments to explore the role of survivin/BIRC5 in glucose metabolism concerning radiation response.ResultsTumoral BIRC5 expression is associated with serum glucose and predicts locoregional disease‐free survival and lower BIRC5 mRNA levels are associated with better outcomes. Upregulation of BIRC5 by radiation depends on glucose levels and provokes a pro‐tumoral and radioresistant phenotype in surviving cells.ConclusionsSurvivin/BIRC5 might be independently associated with the risk of recurrence in patients with HNSCC.

show abstract

Section: Radiation-induced Survivin/birc5 Expression Is Dependent On ...supporting

confidence: 89%

Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma

Benaiges,

Ceperuelo‐Mallafré,

Guaita

et al. 2024

Head & Neck

View full text Add to dashboard Cite

show abstract

“…NY-ESO-1 expression was also found to be patchy (this report); limited access to tumor material may therefore result in false negative results concerning protein expression. NY-ESO-1 and survivin expression was further consolidated by the presence of humoral anti-NY-ESO-1- and survivin-directed IgG responses [ 32 , 33 ] in the current patient cohort (see Supplementary Fig. 5).…”

Section: Discussionmentioning

confidence: 77%

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

Liu

Poiret

Persson

et al. 2017

Cancer Immunol Immunother

View full text Add to dashboard Cite

The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor specimens. T-cells from peripheral blood were stimulated with TAAs (synthetic peptides) in IL-2 and IL-7, or using a combination of IL-2, IL-15 and IL-21. CD4+ and CD8+ T-cells were tested for antigen-specific proliferation by flow cytometry, and IFN-γ production was tested by ELISA. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. We could detect antigen-specific IFN-γ responses in 25% blood samples for NY-ESO-1 and 30% for survivin. NY-ESO-1-expanded T-cells recognized naturally processed and presented epitopes. NY-ESO-1 or survivin expression in glioma represents viable targets for anticancer-directed T-cells for the biological therapy of patients with glioma.Electronic supplementary materialThe online version of this article (doi:10.1007/s00262-017-2066-z) contains supplementary material, which is available to authorized users.

show abstract

“…We also previously reported that autoantibodies against survivin and livin were detected in patients with gastrointestinal, lung, breast and hepatic cancers (9)(10)(11)(12)(13). Other studies also reported survivin autoantibody positivity in various cancers (14)(15)(16)(17)(18). However, there have been no comprehensive studies establishing an ideal detection combination regarding IAPs and other tumor markers.…”

Section: Introductionmentioning

confidence: 93%

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Hosono

Goto

Kobayashi

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Autoantibodies against cancer-related antigens may be detected in the sera of patients with various types of cancer, although their clinical utility has not yet been established. In this study, we aimed to demonstrate the diagnostic relevance of autoantibody detection against inhibitor of apoptosis protein (IAP) family members in colon cancer, as compared to anti-p53 antibody, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9. We established an ELISA system using original recombinant proteins of IAP family members (survivin, livin and X-linked IAP) and measured the expression levels in the sera of 62 healthy donors, 250 patients with colon polyps (adenoma) and 176 patients with colon cancer. When the cutoff value was set as the mean value + 2 standard deviations in healthy donors, anti-survivin exhibited the highest positivity rate (24.4%) among IAP autoantibodies in cancer patients. Furthermore, the anti-survivin antibody exhibited a high positivity rate in early-stage carcinoma and adenoma. In the combination assay, reflecting the significantly high positivity rate of CEA in stage IV tumors, the positivity rate was highest when combining the detection of anti-survivin antibody and CEA in cancer patients (50.0%), indicating that this combination may not be useful for the diagnosis of early-stage cancers. By contrast, reflecting the complete independence of anti-survivin and anti-p53 antibodies, the combination of detecting these two antibodies resulted in the highest positivity rate (35.6%) in early-stage disease (stage 0-I). These results suggest that the combined measurement of anti-survivin and anti-p53 antibodies may be useful for the detection of early-stage colon cancer.

show abstract

Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients

Cited by 3 publications

References 17 publications

Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma

Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Contact Info

Product

Resources

About